Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$16.2 - $23.18 $775,121 - $1.11 Million
47,847 Added 277.25%
65,105 $1.4 Million
Q3 2023

Nov 08, 2023

BUY
$20.63 - $30.17 $356,032 - $520,673
17,258 New
17,258 $356,000
Q1 2023

May 11, 2023

BUY
$21.91 - $32.67 $197,299 - $294,193
9,005 New
9,005 $207,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Campbell & CO Investment Adviser LLC Portfolio

Follow Campbell & CO Investment Adviser LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.